

PRESS RELEASE



CORRECTION - Calgary, Alberta – July 17, 2024 - *For Immediate Release* – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) updates its DNA-related Clinical Study, and Mindbalanced operations.

This news release corrects the date of the Incite Health Inc. agreement as previously announced. The date was previously reported as June 15, 2024 when the date should be July 15, 2024.

The Clinical Study

The Corporation’s belief is that while genetic predispositions can make individuals more susceptible to certain mental health issues, environmental factors play a crucial role in whether these conditions develop and how they progress. For instance, a person with a genetic predisposition to depression may or may not develop the condition depending on their life experiences and other environmental influences. The Corporation also believes that understanding the interplay between genetics and environment is important to better assess mental health issues and develop effective treatments. The essence of the Clinical Study with York University is to investigate the relationship between certain DNA aspects and the extensive environmental factors resident in the records of our Reference Database when predicting probabilities of depression. Based on results to date, the Corporation believes, when using psychiatrist/psychologist diagnoses as the “ground truth”, the inclusion of DNA data results in more comprehensive and nuanced predictions, returning up to 90% positive predictive values depending on optimal tuning and using the current DNA panel. It is believed that a variety of currently-available DNA panels can be incorporated thereby increasing nuance for various medical condition/DNA relationships. It was also found that after the DNA-enhanced model was completed, a different model employing only life/environmental factors and using the same ground truth could predict similar positive predictive values, implying that the different model can return high accuracy analyses without DNA data. These data analysis models do not constitute “diagnoses” rather the predicted probabilities may be considered adjunctive when informing diagnoses and associated treatment programs.

Jim Durward, CEO/CTO states: “Although the Clinical Study is first focused on depression and uses a pharmacogenomic DNA panel, we now believe that the overall process can accommodate other DNA panels that are used in the investigation of drug interactions and neurological predispositions. I am very excited about the potential here.”

Mindbalanced (“MB”) Operations

During the three months since the acquisition, MB has been organizing its operations under a “franchise-style” business model that involves standardized service relationships with clients, DNA data collection and FDA-cleared Transcranial Magnetic Stimulation (“TMS”) treatments for certain mental conditions. The overall concept is to combine the Corporation’s data expertise and databases with new DNA and TMS treatment data to help design personalized treatments for a variety of mental conditions. During the period, contracts were constructed to allow for regulatory variations between US States, a sales pipeline was established, and on Monday, July 15, a contract was signed with Incite Health Inc.

<https://incitehealth.com/> ("IHI") whereby MB will provide marketing and account management services related to IHI's DNA panel offerings.

Joshua Hill, President, states: "This strategic relationship is not only expected to become a material near-term revenue generator, but also carries significant potential to expand the Corporation's Reference Database with DNA-enhanced records which we believe can be combined with TMS treatment data to generate highly-personalized treatment plans."

For Further Information, please contact:

Jim Durward, CEO/CTO (technical and financial matters)

Email: jimd@ndatalyze.com

nDatalyze Website: <https://www.ndatalyze.com>

Joshua Hill, President (Mindbalanced Sales & Marketing matters)

Email: josh@mindbalanced.org

Mindbalanced website: <https://www.mindbalanced.org>

About YMI: YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops, and how to improve mental wellbeing. YMI combines supervised machine-learning with a proprietary Reference Database to predict an individual's predisposition toward a variety of common mental conditions, both current and forward in time. YMI is poised to revolutionize mental health diagnoses while ensuring a sustainable revenue stream. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies, and targeting key markets, YMI aligns both societal impact and financial success.

About Mindbalanced, Inc.: Mindbalanced's vision is to redefine mental healthcare through an integrative, personalized approach leveraging cutting edge technology and non-invasive treatment protocols. By harnessing evidence-based data Mindbalanced aims to predict and enhance mental wellbeing, taking into account individual predispositions and environmental factors thereby fostering healthier and more fulfilling lives for all.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.